Salvage therapy for patients with germ cell tumor

Sawsan Rashdan, Lawrence H. Einhorn

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The introduction of cisplatin combination chemotherapy, 40 years ago, transformed metastatic testicular germ cell tumors from an almost uniformly fatal disease into a model for a curable neoplasm. Before the era of platinum combination chemotherapy, the 5-year survival rate among men with metastatic testicular germ cell tumors was 5% to 10%. Currently, the 5-year survival rate is 80% for patients with metastatic disease and 95% overall. Despite the substantial advances in the treatment of germ cell tumors, 20% to 30% of patients will relapse after first-line chemotherapy and will require additional salvage therapies. Standard-dose or high-dose chemotherapy can cure ≤ 50% of these patients. Relapses after high-dose chemotherapy generally carry a poor prognosis; however, cure is still possible in a small percentage of patients by using further salvage chemotherapy or salvage surgery.

Original languageEnglish (US)
Pages (from-to)437-443
Number of pages7
JournalJournal of oncology practice
Issue number5
StatePublished - May 2016

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy


Dive into the research topics of 'Salvage therapy for patients with germ cell tumor'. Together they form a unique fingerprint.

Cite this